DelveInsight’s, “Gout - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Gout Understanding
    Gout: Overview
    Gout is a common and complex inflammatory arthritis which is characterized by sudden, severe attack of pain in the joints. The disease is caused due to a condition known as hyperuricemia, where there is excess amount of uric acid (a waste material) in the body. Too much uric acid can build up urate crystals that accumulate in the joints, causing inflammation, and intense pain of gout. Presence of excess levels of uric acid in the body can be either due to breakdown of purines which are found in body as well as food that is consumed or insufficient excretion by kidneys. Individuals with diabetes, poor kidney function, metabolic syndrome, obesity are likely to develop hyperuricemia which causes gout. Also, males are more prone to develop gout primarily because women tend to have lower level of uric acid. Joints that are commonly affected include ankles, knees, and the lesser toe joints.

    "Gout - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.

    Gout Emerging Drugs Chapters
    This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Gout Emerging Drugs
    • SEL 212: Selecta Biosciences
    Selecta Bioscience’s lead drug candidate, SEL 212, is a novel combination product consisting of pegadricase (also known as pegsiticase) co-administered with synthetic vaccine particles encapsulating rapamycin (SVP-R). The drug has demonstrated good efficacy and was well tolerated in its phase II trials and is currently being evaluated for the chronic gout in its phase III trials.
    • URC 102: JW Pharmaceuticals
    JW Pharmaceuticals “breakthrough” drug UC-102 is currently being evaluated for the treatment of gout and has demonstrated good safety and efficacy profile in phase II trials. ULC-102 is an antigout small molecule with SLC22A12 protein inhibition mechanism of action and promotes uric acid excretion.
    Further product details are provided in the report??..

    Gout: Therapeutic Assessment
    This segment of the report provides insights about the different Gout drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Gout
    There are approx. 5+ key companies which are developing the therapies for Gout. The companies which have their Gout drug candidates in the mid to advanced stage, i.e. phase III include, Selecta Biosciences and others.

    Phases
    DelveInsight’s report covers around 5+ products under different phases of clinical development like
    • Late-stage products (Phase III)
    • Mid-stage products (Phase II and Phase I/II)
    • Early-stage products (Phase I/II and Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Subcutaneous
    • Intravenous
    • Oral
    • Intramuscular
    • Molecule Type

    Products have been categorized under various Molecule types such as
    • Small molecules
    • Natural metabolites
    • Monoclonal antibodies
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Gout: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.

    Gout Report Insights
    • Gout Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Gout Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Gout drugs?
    • How many Gout drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gout?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gout therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Gout and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Selecta Biosciences
    • JW Pharmaceuticals
    • Astrazeneca
    • Revive Therapeutics
    • Fuji Yakuhin Co., Ltd.
    • Arthrosi Therapeutics

    Key Products
    • SEL 212
    • URC 102
    • Verinurad
    • AR882
    • FYU-981